| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
i
|
|
| Editorial on - The first issue of Drug Resistance Updates |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial
13 February 2012
Drug Resistance Updates was launched in January 1998. From the very beginning, Dr. Henk Broxterman, an expert in the field of multidrug resistance and tumor angiogenesis and an associate professor at ...
|
Christian G. Giske,
Jos Jonkers
|
1
|
|
| Editorial on - Multidrug resistance 35 years after ABCB1 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1
05 April 2012
Drug resistance is a major public health problem that dramatically affects the efficacy of cancer treatment. When resistance to either systemic or targeted drug treatment occurs, tumor cells may becom...
|
Jean-Pierre Gillet,
Michael M. Gottesman
|
2-4
|
|
| Reviews |
| |
Article Title |
Author(s) |
Pages |
|
|
|
Contribution of tumoral and host solute carriers to clinical drug response
30 March 2012
Abstract: Members of the solute carrier family of transporters are responsible for the cellular uptake of a broad range of endogenous compounds and xenobiotics in multiple tissues. Several of these so...
|
Jason A. Sprowl,
Torben S. Mikkelsen,
Hugh Giovinazzo,
Alex Sparreboom
|
5-20
|
|
|
|
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
22 February 2012
Abstract: Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to drug resistance su...
|
Roel H. Wilting,
Jan-Hermen Dannenberg
|
21-38
|
|
|
|
The tumor microenvironment is a dominant force in multidrug resistance
15 February 2012
Abstract: The emergence of clinical drug resistance is still one of the most challenging factors in cancer treatment effectiveness. Until more recently, the assumption has been that random genetic les...
|
Ana Luísa Correia,
Mina J. Bissell
|
39-49
|
|
|
|
Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
05 April 2012
Abstract: This special issue of Drug Resistance Updates is dedicated to multidrug resistance protein 1 (MDR-1), 35 years after its discovery. While enormous progress has been made and our understandin...
|
Laleh Amiri-Kordestani,
Agnes Basseville,
Karen Kurdziel,
Antonio Tito Fojo,
Susan E. Bates
et al.
|
50-61
|
|
|
|
Drug resistance: Still a daunting challenge to the successful treatment of AML
14 March 2012
Abstract: Resistance to chemotherapy remains a challenging issue for patients and their physicians. P-glycoprotein (Pgp, MDR1, ABCB1), as well as a family of structurally and functionally related prot...
|
Brian C. Shaffer,
Jean-Pierre Gillet,
Chirayu Patel,
Maria R. Baer,
Susan E. Bates,
Michael M. Gottesman
et al.
|
62-69
|
|
|
|
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
13 February 2012
Abstract: Tyrosine kinases (TKs) are involved in key signaling events/pathways that regulate cancer cell proliferation, apoptosis, angiogenesis and metastasis. Deregulated activity of TKs has been imp...
|
Suneet Shukla,
Zhe-Sheng Chen,
Suresh V. Ambudkar
|
70-80
|
|
|
|
Drug resistance in the mouse cancer clinic
15 February 2012
Abstract: Drug resistance is one of the most pressing problems in treating cancer patients today. Local and regional disease can usually be adequately treated, but patients eventually die from distant...
|
Sven Rottenberg,
Piet Borst
|
81-89
|
|
|
|
The dynamics of drug resistance: A mathematical perspective
05 March 2012
Highlights: ► We review the aspects of MDR that have been mathematically studied. ► We explain how mathematics can be used to study drug resistance. ► We demonstrate how mathematics can be used in com...
|
Orit Lavi,
Michael M. Gottesman,
Doron Levy
|
90-97
|
|
|
|
Collateral sensitivity as a strategy against cancer multidrug resistance
09 April 2012
Abstract: While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approximately 90% of treatment failure. Multidrug resistan...
|
Kristen M. Pluchino,
Matthew D. Hall,
Andrew S. Goldsborough,
Richard Callaghan,
Michael M. Gottesman
et al.
|
98-105
|
|
|
|
Immunotherapy: A useful strategy to help combat multidrug resistance
09 April 2012
Abstract: Multidrug resistance (MDR) renders cancer cells relatively invulnerable to treatment with many standard cytotoxic anti-cancer agents. Cancer immunotherapy could be an important adjunct for o...
|
Tyler J. Curiel
|
106-113
|
|
|
|
Starvation, detoxification, and multidrug resistance in cancer therapy
05 March 2012
Abstract: The selection of chemotherapy drugs is based on the cytotoxicity to specific tumor cell types and the relatively low toxicity to normal cells and tissues. However, the toxicity to normal cel...
|
Changhan Lee,
Lizzia Raffaghello,
Valter D. Longo
|
114-122
|
|
|
|
Cellular senescence and cancer chemotherapy resistance
27 February 2012
Abstract: Innate or acquired resistance to cancer therapeutics remains an important area of biomedical investigation that has clear ramifications for improving cancer specific death rates. Importantly...
|
Ryan R. Gordon,
Peter S. Nelson
|
123-131
|
|
